Bionano Stock Retains Its ‘Strong Buy’ Status
if Bionanos (BNGO† optical genome mapping (OGM) system Saphyr is to gain mainstream adoption, it has to show its performance improves on standard of care (SOC) methods. So far, it appears to be doing just that. There have been several publications so far demonstrating its usefulness and on Friday, the company announced the first publication … Read more